Empowering the Next Generation: Aurora Announces German Internship Program

NASDAQ | TSX: ACB

Company Launches Internships at Manufacturing Facility in Leuna, Germany to Cultivate Future Leaders in the Medical Cannabis Industry

EDMONTON, AB, Jan. 10, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce the launch of an internship program at Aurora's leading EU-GMP facility in Leuna, Germany. In partnership with Erfurt University of Applied Sciences, students of the Horticultural Crop Production course will gain valuable hands-on experience on-site and deepen their understanding of medical cannabis cultivation. Aurora's investment in future industry leaders is one of the many ways Aurora is expanding the frontiers of global medical cannabis.

"We are thrilled to be giving these students the opportunity to collaborate with our leading experts in the global medical cannabis industry, providing them with unparalleled insights and skills," says Michael Simon, President of Aurora Europe (Interim). "We are committed to nurturing talent and fostering a collaborative environment, ensuring that our interns leave with an enriched understanding of the industry and a solid foundation for their professional journeys."

Aurora's domestic cannabis facility located in Leuna, Saxony-Anhalt, is one of the few sites in Germany permitted to grow medical cannabis. The state-of-the-art indoor facility meets the highest standards of operational excellence, using innovative and sustainable cultivation methods, making it an ideal site for students to learn best practices.

The six-month internship program will focus on all phases of medical cannabis cultivation, including cloning, care, harvesting, packaging and cleaning. Students will also participate in special research and development projects.

Aurora's proven expertise in not only developing premium medical cannabis products, but in cultivating great talent, both domestically and globally, has allowed the company to maintain its leadership position as the largest global medical cannabis company operating in nationally legal markets.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at   www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information   

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's German internship partnership, the Company's expansion of the frontiers of global medical cannabis and investment in future industry leaders, and the Company's continued leadership position as the largest global medical cannabis company operating in nationally legal markets.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/empowering-the-next-generation-aurora-announces-german-internship-program-302347597.html

SOURCE Aurora Cannabis Inc.